Genentech's Divarasib Cuts KRAS G12C Lung Cancer Death Risk by 44% in Phase III Trial

The Quick Take

• Genentech's divarasib demonstrated best-in-class KRAS G12C inhibitor efficacy in the Phase III Krascendo 1 study, lowering disease progression or death risk by 42% and overall death risk by 44% versus first-generation inhibitors.
• The Phase III data supports divarasib as a superior standard of care in previously treated KRAS G12C-mutated lung cancer, strengthening Roche/Genentech's oncology pipeline valuation.
• KRAS G12C inhibitors represent a large addressable oncology market; best-in-class efficacy data creates competitive pressure for Amgen's Sotorasib (AMG 510) and Mirati's Adagrasib.

Synthesized from 1 source.

Genentech's divarasib demonstrated superior efficacy versus first-generation KRAS G12C inhibitors in the Phase III Krascendo 1 trial, reducing the risk of disease progression or death by 42% and the risk of overall death by 44% in previously treated patients with KRAS G12C-mutated non-small cell lung cancer. The results, described as best-in-class by Genentech, were presented via Financial Post's Newswire channel. Divarasib's data establishes it as a potential new standard of care in a KRAS G12C patient population that has historically lacked highly effective targeted therapies.

The Phase III data has significant competitive implications for the KRAS G12C inhibitor class. Amgen's Sotorasib (Lumakras/AMG 510) was the first approved KRAS G12C inhibitor, and Mirati's Adagrasib was the second entrant — but divarasib's 42-44% superiority on PFS and OS endpoints versus first-generation inhibitors represents a substantial clinical differentiation that could shift market share in this segment. Roche's stock and Genentech's embedded pipeline value will reflect the regulatory approval pathway and pricing potential in the KRAS G12C lung cancer segment, which spans multiple treatment lines and indications.

Key signals to watch include the FDA submission and review timeline for divarasib based on the Krascendo 1 data, Roche's health technology assessment negotiations in European markets, and competitive responses from Amgen on next-generation Sotorasib combinations. The macro variable is the biotech regulatory environment: FDA oncology approvals under the current administration and the pace of breakthrough therapy designations will determine how quickly divarasib reaches commercial markets. A positive AdCom or Priority Review designation would be a strong upside catalyst for Roche/Genentech's oncology pipeline valuation.